Progressive supranuclear palsy
Not recruitingStudy of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)
Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)
- Disease:Progressive supranuclear palsy
- Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
Germany- Participants:18–64 years · 65+ years
- Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
- Sponsor:Ferrer Internacional S.A.











